PCRX: Pacira BioSciences, Inc. Stock

by  •  • Comments Off on PCRX: Pacira BioSciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,224.96
Enterprise Value ($M) 1,594.09
Book Value ($M) 870.13
Book Value / Share 18.70
Price / Book 1.41
NCAV ($M) -194.26
NCAV / Share -4.18
Price / NCAV -6.31

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.05

Liquidity (mrq)
Quick Ratio 4.17
Current Ratio 5.24

Balance Sheet (mrq) ($M)
Current Assets 509.99
Assets 1,574.39
Liabilities 704.26
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 674.98
Operating Income 92.47
Net Income 41.95
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 154.65
Cash from Investing 77.54
Cash from Financing -183.03

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 10.98 3.52
01-19 13G/A BlackRock Inc. 17.50 11.90

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 Or ☐ TRANSITION REPORT PU
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPO
2023-08-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-29 76,298 333,061 22.91
2024-04-26 46,002 139,758 32.92
2024-04-25 52,088 134,315 38.78
2024-04-24 56,451 154,473 36.54

(click for more detail)

Similar Companies
OVID – Ovid Therapeutics Inc. PASG – Passage Bio, Inc.
PBYI – Puma Biotechnology, Inc. PCVX – Vaxcyte, Inc.
PEPG – PepGen Inc.


Financial data and stock pages provided by
Fintel.io